RichardK.ValicentiMDMA, FASTRO
Radiation Oncology • Sacramento, CAUrologic Cancer
Chair and Professor, Radiation Oncology, UC, Davis School of Medicine
Dr. Valicenti is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4501 X St
# Ground
Sacramento, CA 95817Phone+1 916-734-8295Fax+1 916-734-3239
Summary
- Dr. Richard Valicenti is a radiation oncologist in Sacramento, CA and is affiliated with University of California, Davis Medical Center. He received his medical degree from Drexel University College of Medicine and has been in practice 27 years. He specializes in urologic cancer and is experienced in adenocarcinoma, intensity-modulated radiation therapy, 3d conformal radiation therapy, prostate seed therapy, and combined modality therapy.
Education & Training
Washington University/B-JH/SLCH ConsortiumResidency, Radiation Oncology, 1991 - 1995
Drexel University College of Medicine/Hahnemann University HospitalInternship, Internal Medicine, 1990 - 1991- Drexel University College of MedicineClass of 1990
Certifications & Licensure
CA State Medical License 2009 - 2026
PA State Medical License 1990 - 2014
NJ State Medical License 2003 - 2005- American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- Castle Connoly America’s Top Doctor 2012-2019
- Best Doctor of America 2008-2019
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2012
- Join now to see all
Clinical Trials
- Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer Start of enrollment: 2001 Aug 01
- Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer Start of enrollment: 2003 Mar 01
- Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer Start of enrollment: 2008 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 8 citationsNoninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Cli...Mark K Buyyounouski, Stephanie L Pugh, Ronald C Chen, Mark J Mann, Rajat J Kudchadker
JAMA Oncology. 2024-05-01 - 24 citationsNCCN Guidelines® Insights: Prostate Cancer, Version 3.2024.Edward M Schaeffer, Sandy Srinivas, Nabil Adra, Yi An, Rhonda Bitting
Journal of the National Comprehensive Cancer Network. 2024-04-01 - 21 citationsStereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (A...Giulio Francolini, Andrea Gaetano Allegra, Beatrice Detti, Vanessa Di Cataldo, Saverio Caini
Journal of Clinical Oncology. 2023-12-20
Press Mentions
Versa Blue Brings Advanced Radiation Treatment to Cancer PatientsMarch 31st, 2021- CCR Score Could Offer ADT-Free Path in Higher-Risk Prostate CancerFebruary 12th, 2021
ASTRO and AUA Announce Updates to Joint Clinical Guidance for Adjuvant and Salvage Radiotherapy After ProstatectomyMay 1st, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
